The New Mexico Dermatology and Dermatologic Surgery Society was organized to promote and advance the science and art of medicine pertaining to diseases of the skin and to promote the highest possible standards in clinical practice, education and research in dermatological medicine and surgery.
NMDDSS focuses on:
Education – Providing dermatology CME opportunities in New Mexico and partnering with the University of New Mexico
Advovacy – Working with New Mexico Medical Association and the American Academy of Dermatology to advocate for our patients, members and the profession
Outreach – Coming together to provide much needed services and screenings for the people of New Mexico
Leadership
President – Michael B. Chang, MD
Dr. Chang is a board-certified dermatologist and fellowship-trained dermatologic surgeon. After graduating from Stanford University, Dr. Chang completed his medical training at the University of Maryland School of Medicine in Baltimore, Maryland. His post-graduate training included a residency in dermatology at Mayo Clinic in Rochester, Minnesota, followed by a fellowship in Micrographic Surgery and Dermatologic Oncology also at Mayo Clinic.
Walter Burgdorf, MD Memorial Lectureship Held September 27-28th
NMDDSS and the University of New Mexico School of Medicine Department of Dermatology held the 9th Annual Walter Burgdorf, MD Memorial Lectureship in September. We had nationally known speakers Bill James, MD and Klint Peebles, MD, as well as case presentations, resident programs updates and an alumni presentation. The conference also included social events to foster networking in a collegial environment.
News
UNM Dermatology Currently Enrolling Clinical Trials
Cutaneous Lupus Amethyst study-
230LE301 (AMETHYST) is a study to assess the efficacy and safety of BIIB059 (Litifilimab) in participants with active subacute cutaneous lupus erythematosus (SCLE) and/or chronic cutaneous lupus erythematosus (CCLE) with or without systemic manifestations and refractory and/or intolerant to antimalarial therapy.
Non-Segmental Vitiligo Tranquillo Study-
B7981040 (Tranquillo) is a Phase 3 randomized, double-blind, 52-week placebo-controlled, multi-center study investigating the efficacy, safety, and tolerability of ritlecitinib in adult and adolescent participants with non-segmental vitiligo (both active and stable vitiligo). More Information
Murad Alam, MD, FAAD, elected American Academy of Dermatology president for 2026
Chicago-based board-certified dermatologist Murad Alam, MD, FAAD, has been elected to lead the American Academy of Dermatology. He will be installed as president-elect in March 2025 and hold the office of president for one year beginning in March 2026. More Information
Academy response to benzene petition on benzoyl peroxide products
The American Academy of Dermatology Association is aware of a recent petition filed with the FDA describing formation of benzene in products containing benzoyl peroxide that are exposed to elevated temperatures. More Information
Military members more at risk for melanoma
U.S. veterans are at a higher risk of developing melanoma, one of the deadliest forms of skin cancer, likely due in part to the occupational hazards associated with active duty in countries near the equator where ultraviolet (UV) levels are higher. More Information
Become a Member!
NMDDSS Membership has many benefits. Visit our membership page for details or contact us a NewMexicoDermSociety@gmail.com for more information.
Download the Membership Application
2025 Memberships Dues
For current members, you can pay your 2025 dues on line
Events
SAVE THE DATE
NMDDSS 2025 Spring Conference
April 4-5th in Albuquerque
More Details Soon
_____________________
Registration for the AAD Annual Meeting opens November 20!